On November 1, 2022, at the 2022 Shenzhen Global Innovation Talent Forum, the famous scientist Yan Ning announced that he resigned from Princeton University and founded the Academy of Medical Sciences in Shenzhen, and then rushed to the hot search, and netizens welcomed back.
On July 4, the European Molecular Biology Organization announced the list of 69 newly selected members (9 foreign members), and Yan Ning, as a Chinese scientist, was elected as a foreign member of EMBO (Associate Member).
Yan Ning is a structural biologist, president of Shenzhen Academy of Medical Sciences, director of Shenzhen Bay Laboratory, foreign academician of the National Academy of Sciences, foreign academician of the American Academy of Arts and Sciences, the first "International Young Scientist" of the Howard Hughes Medical Institute, and a member of the Chinese Academy of Medical Sciences.
Yan Ning is committed to the study of the structure and mechanism of transmembrane transport of substances, and for the first time reveals the atomic-resolution structures of a series of transmembrane proteins with important physiological and pathological significance, such as human glucose transporters, eukaryotic voltage-gated sodium ion channels and calcium ion channels, which provides a molecular basis for understanding the pathogenic mechanism of related diseases and drug development.
The competitive landscape of the global biomedical industry
——4 Chinese pharmaceutical companies in the TOP50 global pharmaceutical companies were listed
According to the 2022 TOP50 list of global pharmaceutical companies released by Harm Exec, Pfizer of the United States, AbbVie of the United States, and Novartis of Switzerland are in the top three; Among the top 50 companies, 15 US companies are on the list, 7 Japanese companies are on the list, and 4 Chinese and German companies are on the list. Among them, the Chinese companies on the list are Hengrui Pharmaceutical, China Biopharmaceutical, Shanghai Pharmaceutical and CSPC Pharmaceutical Group, ranking 32, 40, 41 and 43 respectively.
- Pfizer ranked first in the global pharmaceutical company total revenue ranking in 2022
In terms of revenue, the global top 10 biopharmaceutical companies in 2022 are shown in the following table, of which Pfizer ranks first with a total revenue of $100.33 billion.
Regional competitive landscape
North America accounted for the largest share of global revenue
North America accounted for the highest proportion of global biomedical market revenue, reaching 49%; It is followed by Europe, China and Japan, with pharmaceutical market revenue accounting for 23%, 9% and 6% respectively.
——The advantages of biomedical industrial park clusters are obvious
To build a biomedical industry cluster, it is mainly necessary to meet the construction of a scientific research environment for universities and improve the design of a close cooperation mechanism between universities, investment institutions and enterprises. The global biomedical industry takes the high-density agglomeration of universities as the source, forming the development of industrial park cluster model and the "four-in-one" element agglomeration pattern. Among them, the industrial park clusters in the United States and Europe have obvious advantages.
In the future, the global biomedical industry will have the development trend of intensifying global competition, further improving market concentration, accelerating industrial cluster effect, and highly coordinated industrial division of labor.
Foresight Economist APP Information Group
For more information on the research and analysis of this industry, please refer to the "2023-2028 China Biomedical Industry In-depth Research and Investment Strategic Planning Analysis Report" by the Prospective Industry Research Institute.
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment promotion, industrial map, intelligent investment promotion system, industry status certification, IPO consultation/fundraising feasibility study, IPO working paper consultation and so on. Quoting the content of this article in any public information disclosure such as prospectus and annual report of the company requires formal authorization from the Prospective Industry Research Institute.
More in-depth industry analysis can be found in the [Prospective Economist APP], and you can also interact with 500+ economists/senior industry researchers.